表紙
市場調查報告書
商品編碼
1071655

帕金森病生物標誌物的全球市場洞察:2028 年

Global Parkinson Disease Drug Biomarkers Insight 2028

出版日期: | 出版商: Biomarkers Insights | 英文 510 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

到 2028 年,帕金森病生物標誌物的全球市場預計將超過 80 億美元,這主要是由於該病的全球患病率不斷上升。此外,潛在管道產品的存在、加強的研究和積極的政府支持預計將在預測期內推動市場的增長。

本報告探討了全球帕金森病生物標誌物市場,概述了進入市場的公司的市場、細分趨勢、價格分析和競爭條件。

目錄

第一章全球帕金森病藥物市場概況

  • 當前市場趨勢
  • 區域市場分析

第二章全球帕金森病藥物市場未來展望

第 3 章左旋多巴/卡比多巴治療藥物-可用性、劑量和價格分析

  • 多巴/多多巴
  • 麗塔利
  • 電影
  • 左旋多巴吸入器
  • 雷卡多
  • 瘋狂的

第4章多巴胺激動劑-可用性、劑量和價格分析

  • 羅替戈汀 (Neupro)
  • 普拉克索
  • 羅匹尼羅
  • 阿撲嗎啡
  • 溴隱亭

第5章MAO B抑製劑-可用性、劑量和價格分析

  • 司來吉蘭
  • Safinamide (Xadago)
  • 雷沙吉蘭

第6章兒茶酚-O-甲基轉移□(COMT)抑製劑-可用性、劑量和價格分析

  • 恩他卡朋
  • 託卡彭
  • 左旋多巴/卡比多巴/恩他卡朋
  • 奧皮卡彭

第 7 章其他抗帕金森病療法-可用性、劑量和價格分析

  • 苯扎托品
  • 金剛烷胺
  • Istradefylline (Nourianz)
  • 卡巴拉汀
  • 苯並塞吩

第 8 章逐步深入了解全球帕金森病治療的臨床管道和生物標誌物

  • 調查
  • 臨床前
  • 臨床
  • 階段 0
  • 第一階段
  • 一期/二期
  • 第二階段
  • 二期/三期
  • 第三階段
  • 預註冊
  • 已註冊

第9章帕金森病藥物生物標誌物洞察發布

第10章競爭態勢

  • AbbVie
  • Acadia Pharmaceuticals
  • Amenal Pharmaceuticals
  • AstraZeneca
  • Biogen
  • Bristol Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Lundbeck
  • Merck
  • Orion Corporation
  • Roche
  • Teva Pharmaceutical
  • UCB
  • Zydus Cadila
目錄

“Global Parkinson Disease Drug Biomarkers Insight 2028” Report Highlights:

  • Global Parkinson's Disease Antibodies Market Opportunity: > USD 8 Billion
  • Parkinson's Disease Clinical Trials Insight: > 300 Drugs In Trials
  • Parkinson's Disease Biomarkers Sourced During Clinical Trials
  • Parkinson's Disease Insight By Classification
  • Insight On Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

Parkinson disease is second most frequently occurring neurodegenerative disease which is characterized by the progressive loss of dopaminergic neurons. The pathology of Parkinson disease is highly complex and consists of combination of genetics, epigenetics and environmental factors. Most of the symptoms associated with the development of disease generally appear at advanced stage where most of the dopaminergic neurons have been already damaged. Therefore, in order to provide a better clinical intervention and treatment, there is unmet need for the identification of novel biomarkers for the early diagnosis of the disease. At the same time, potential biomarkers can also be used to monitor the progress of the disease. Biomarkers, as indicators of normal physiological or pathological processes, are always involved in disease mechanisms.

To date, several motor symptoms of bradykinesia, resting tremor and muscle rigidity are considered as the most significant and direct diagnostic marker for Parkinson disease. Further for the early diagnosis of disease, many non-motor features, including hyposmia, rapid eye movement (REM) sleep behavior disorder, and constipation have also gained considerable interest among research studies. In addition to these clinical biomarkers, researchers have also identified several potential biochemical markers found in blood, saliva, cerebrospinal fluid (CSF) and biopsies. Mitochondrial dysfunction, oxidative stress, Lewy body's formation, neuroinflammation and other mechanisms have gained the maximum interest as they are involve in the physiology of the disease.

Further, neuroimaging methodologies have also become a mature biomarker for the nigrostriatal neurodegeneration by analyzing the potential structure, ultrastructural, or perfusion pattern changes in parkinson. An increasing number of neuroimaging technologies can be used to detect early changes in Parkinson disease patients and assess progression of the disease, less susceptible to the effects of subjectivity and drugs. These biomarkers have entered the clinical trial and most of them are used as surrogate outcomes for investigating the biological efficacy of a treatment. Apart from this, other biomarkers including microRNA, peptides, and genetic biomarkers have also been identified which are present in early stages of clinical trials.

In addition to this, several ongoing research studies have been exploring new approaches to discover novel biomarkers for Parkinson disease. However, the high complexity of the disease etiology and physiology, there is need for comprehensive identification of signaling pathways which aid in better understanding of the disease and development of more effective biomarkers. The advent of omic technology including genomics, transcriptomics, proteomics and metabolomics are also being applied in the study of Parkinson disease biomarkers, which will drive the growth of market during the forecast period.

As per our report findings the global Parkinson disease biomarker market will surpass US$ 8 Billion by 2028 which is mainly attributed to the increase in prevalence of the disease globally. Further, presence of potential pipeline products, increased research and active government support is also expected to drive the growth of the market during the forecast period. The introduction of affordable biomarker testing, growing demand for non-invasive diagnostic technologies, and rise in number of clinical trials are also expected to drive the growth of market during the forecast period.

This report on global Parkinson disease biomarkers market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. Our report provides comprehensive analysis on the approved biomarkers for Parkinson disease drugs. Apart from this, in-depth analysis on the ongoing clinical trials in biomarkers associated with novel targeted drugs in development by various phases is also mentioned in the report.

Table of Contents

1. Global Parkinson's Drug Market Overview

  • 1.1. Current Market Trends
  • 1.2. Regional Market Analysis

2. Global Parkinson's Drug Market Future Outlook

3. Levodopa/Carbidopa Therapeutics - Availability, Dosage & Price Analysis

  • 3.1. Duopa/Duodopa
  • 3.2. Rytary
  • 3.3. Sinemet
  • 3.4. Levodopa Inhaler
  • 3.5. Lecado
  • 3.6. Madopar

4. Dopamine Agonist - Availability, Dosage & Price Analysis

  • 4.1. Rotigotine (Neupro)
  • 4.2. Pramipexole
  • 4.3. Ropinirole
  • 4.4. Apomorphine
  • 4.5. Bromocriptine

5. MAO B Inhibitors - Availability, Dosage & Price Analysis

  • 5.1. Selegiline
  • 5.2. Safinamide (Xadago)
  • 5.3. Rasagiline

6. Catechol O-methyltransferase (COMT) inhibitors - Availability, Dosage & Price Analysis

  • 6.1. Entacapone
  • 6.2. Tolcapone
  • 6.3. Levodopa /Carbidopa /Entacapone
  • 6.4. Opicapone

7. Other Anti-Parkinson's Drugs - Availability, Dosage & Price Analysis

  • 7.1. Benztropine
  • 7.2. Amantidine
  • 7.3. Istradefylline (Nourianz)
  • 7.4. Rivastigmine
  • 7.5. Trihexyphenidyl

8. Global Parkinson's Disease Drugs Clinical Pipeline & Biomarkers Insight By Phase

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Clinical
  • 8.4. Phase-0
  • 8.5. Phase-I
  • 8.6. Phase-I/II
  • 8.7. Phase-II
  • 8.8. Phase-II/III
  • 8.9. Phase-III
  • 8.10. Preregistration
  • 8.11. Registered

9. Marketed Parkinson's Disease Drugs Biomarkers Insight

10. Competitive Landscape

  • 10.1. AbbVie
  • 10.2. Acadia Pharmaceuticals
  • 10.3. Amenal Pharmaceuticals
  • 10.4. AstraZeneca
  • 10.5. Biogen
  • 10.6. Bristol Myers Squibb
  • 10.7. Gilead Sciences
  • 10.8. GlaxoSmithKline
  • 10.9. Lundbeck
  • 10.10. Merck
  • 10.11. Orion Corporation
  • 10.12. Roche
  • 10.13. Teva Pharmaceutical
  • 10.14. UCB
  • 10.15. Zydus Cadila

List of Figures

  • Figure 1-1: Global - Parkinson Drug Disease Market Size (US$ Billion), 2020 & 2021
  • Figure 1-2: US - Parkinson Disease Incidences (Million), 2020 & 2030
  • Figure 1-3: US vs. ROW - Parkinson Drug Disease Market (US$ Billion), 2021
  • Figure 1-4: US vs. ROW - Parkinson Drug Disease Market (%), 2021
  • Figure 1-5: Parkinson Disease Market Size by Region (US$ Billion), 2021
  • Figure 1-6: Parkinson Disease Market Size by Region (%), 2021
  • Figure 2-1: Global - Parkinson Drug Disease Market Size (US$ Billion), 2022 - 2028
  • Figure 2-2: US - Parkinson Drug Disease Market Size (US$ Billion), 2022 - 2028
  • Figure 3-1: Duopa - FDA Orphan Designation & FDA Approval Year
  • Figure 3-2: Duopa/Duodopa - Approval Year by Region
  • Figure 3-3: US - Duopa FDA Approval & Patent Expiration Year
  • Figure 3-4: US - Cost of Supply of 700ml, 100ml & Per Unit Price of Duopa 4.3-20mg/ml Suspension (US$), April'2022
  • Figure 3-5: UK - Cost of Supply of 700ml, 100ml & Per Unit Price of Duodopa Intestinal Gel (GBP /US$), April'2022
  • Figure 3-6: US - Maximum Daily, Monthly & Annual Treatment Cost of Duopa for Parkinson's Treatment (US$), April'2022
  • Figure 3-7: Global - Duopa/Duodopa Annual Sales Value (US$ Million), 2018-2021
  • Figure 3-8: US - Duopa/Duodopa Annual Sales Value (US$ Million), 2018-2021
  • Figure 3-9: ROW - Duopa/Duodopa Annual Sales Value (US$ Million), 2018-2021
  • Figure 3-10: Duopa/Duodopa - Global Sales Value by Region (US$ Million), 2021
  • Figure 3-11: Duopa/Duodopa - Global Sales Value by Region (%), 2021
  • Figure 3-12: Duopa/Duodopa - Global Sales Value by Region (US$ Million), 2021
  • Figure 3-13: Duopa/Duodopa - Global Sales Value by Region (%), 2020
  • Figure 3-14: Global - Duopa/Duodopa Quarterely Sales Value (US$ Million), 2021
  • Figure 3-15: US - Duopa/Duodopa Quarterely Sales Value (US$ Million), 2021
  • Figure 3-16: ROW - Duopa/Duodopa Quarterely Sales Value (US$ Million), 2021
  • Figure 3-17: Global - Duopa/Duodopa Quarterely Sales Value (US$ Million), 2020
  • Figure 3-18: US - Duopa/Duodopa Quarterely Sales Value (US$ Million), 2020
  • Figure 3-19: ROW - Duopa/Duodopa Quarterely Sales Value (US$ Million), 2020
  • Figure 3-20: US - Number of Rytray Patents Issued in Different Years
  • Figure 3-21: US - Rytary Patent Approval & Expiration Year
  • Figure 3-22: US - Cost of Supply of 100 & Price per Unit of Rytray 23.75-95mg, 36.25-145 mg & 48.75-195mg Dose Capsules (US$), April'2022
  • Figure 3-23: US - Cost of Supply of 240 & Price per Unit of Rytray 23.75-95mg, 36.25-145 mg & 48.75-195mg Dose Capsules (US$), April'2022
  • Figure 3-24: US - Cost of Supply of 100 & Price per Unit of Rytray 61.25-2455mg Dose Capsules (US$), April'2022
  • Figure 3-25: Rytray - Recommended Initial, Incremented & Maximum Dose for Treatment Parkinson's Patient Naïve to Levodopa Therapy (mg/day)
  • Figure 3-26: Global - Rytary Quarterely Sales Value (US$ Thousand), 2019 & 2020
  • Figure 3-27: US - Sinemet FDA Approval & 1st Generic Approval Year
  • Figure 3-28: US - Cost of Supply of 100 Tablets & Price per Unit of Sinemet 10-100mg Tablet (US$), April'2022
  • Figure 3-29: US - Cost of Supply of 100 Tablets & Price per Unit of Sinemet 25-100mg Tablet (US$), April'2022
  • Figure 3-30: US - Cost of Supply of Various Tablets of Carbidopa/Levodopa 10-100mg Tablet (US$), April'2022
  • Figure 3-31: US - Cost of Supply of Various Tablets of Carbidopa/Levodopa 25-250mg Tablet (US$), April'2022
  • Figure 3-32: US - Cost of Supply of Various Tablets of Carbidopa/Levodopa 25-100mg Tablet (US$), April'2022
  • Figure 3-33: Sinemet - Recommended Initial & Maximum Dose (mg/day)
  • Figure 3-34: Inbrija - Approval Year by Region
  • Figure 3-35: US - Inbrija Patent Approval & Expiration Year
  • Figure 3-36: US - Cost of Supply of 60 Capsules & Price per Unit of Inbrija inhalation Capsule (US$), April'2022
  • Figure 3-37: Inbrija - Recommended Initial & Maximum Dose For Parkinson's Treatment (mg/day)
  • Figure 3-38: Inbrija - Recommended Initial & Maximum Tablets For Parkinson's Treatment
  • Figure 3-39: Global - Inbrija Annual Sales Value (US$ Million), 2019 - 2021
  • Figure 3-40: Global - Inbrija Quarterely Sales Value (US$ Million), 2021
  • Figure 3-41: Global - Inbrija Quarterely Sales Value (US$ Million), 2020
  • Figure 3-42: UK - Cost of Supply of 60 Tablets & Per Unit Price of Lecado Oral Tablet (GBP/US$), April'2022
  • Figure 3-43: Lecado - Recommended Initial & Maximum Tablets For Parkinson's Treatment
  • Figure 3-44: UK - Cost of Supply of 100 Capsules of Madopar Oral Capsule by Strength (GBP/US$), April'2022
  • Figure 3-45: Madopar - Recommended Initial & Maximum Capsules For Parkinson's Treatment
  • Figure 4-1: Neupro - Approval Year by Region
  • Figure 4-2: US - Neupro Patent Approval & Expiration Year
  • Figure 4-3: US - Cost of Supply of 30 Transdermal Films & Price per Unit of Neupro Transdermal Film (US$), April'2022
  • Figure 4-4: UK - Cost of Supply of 28 Transdermal Patches & Price per Unit of Neupro 1mg/24hr Transdermal Patch (GBP/US$), April'2022
  • Figure 4-5: UK - Cost of Supply of 28 Transdermal Patches & Price per Unit of Neupro 2mg/24hr Transdermal Patch (GBP/US$), April'2022
  • Figure 4-6: UK - Cost of Supply of 28 Transdermal Patches & Price per Unit of Neupro 4mg/24hr Transdermal Patch (GBP/US$), April'2022
  • Figure 4-7: UK - Cost of Supply of 28 Transdermal Patches & Price per Unit of Neupro 6mg/24hr Transdermal Patch (GBP/US$), April'2022
  • Figure 4-8: Neupro - Initial & Maximum Recommended Dose for Early Stage Parkinson's (mg/day)
  • Figure 4-9: Neupro - Initial & Maximum Recommended Dose for Late Stage Parkinson's (mg/day)
  • Figure 4-10: Global - Neupro Annual Sales (Euro/US$ Million), 2019 - 2021
  • Figure 4-11: Global - Neupro Annual Sales by Region (Euro/US$ Million), 2021
  • Figure 4-12: Global - Neupro Annual Sales by Region (%), 2021
  • Figure 4-13: Global - Neupro Annual Sales by Region (Euro/US$ Million), 2020
  • Figure 4-14: Neupro - Annual Sales Value by Region (%), 2020
  • Figure 4-15: Global - Neupro Annual Sales by Region (Euro/US$ Million), 2019
  • Figure 4-16: Global - Neupro Half Year Sales by Region (Euro/US$ Million), H1'2021
  • Figure 4-17: Neupro - Half Year Sales Value by Region (%), H1'2021
  • Figure 4-18: Pramipexole - Approval Year by Brand Name
  • Figure 4-19: US - Mirapex FDA Approval & 1st Generic Approval Year
  • Figure 4-20: US - Mirapex ER FDA Approval & 1st Generic Approval Year
  • Figure 4-21: US - Cost of Supply of 7 Tablets & Price per Unit of Mirapex ER Tablet (US$), April'2022
  • Figure 4-22: US - Cost of Supply of 30 Tablets & Price per Unit of Mirapex ER Tablet (US$), April'2022
  • Figure 4-23: US - Cost of Supply of 90, 500 & 1000 Pramipexole 0.125mg Oral Tablets (US$), April'2022
  • Figure 4-24: US - Cost of Supply of 90, 100, 500 & 1000 Pramipexole 0.25mg Oral Tablets (US$), April'2022
  • Figure 4-25: US - Cost of Supply of 90, 100, 500 & 1000 Pramipexole 0.5mg Oral Tablets (US$), April'2022
  • Figure 4-26: US - Cost of Supply of 90, 500 & 1000 Pramipexole 0.75mg Oral Tablets (US$), April'2022
  • Figure 4-27: US - Cost of Supply of 30, 90, 500 & 1000 Pramipexole 1mg Oral Tablets (US$), April'2022
  • Figure 4-28: US - Cost of Supply of 90, 500 & 1000 Pramipexole 1.5mg Oral Tablets (US$), April'2022
  • Figure 4-29: US - Cost of Supply of 30 Pramipexole Extended Release Tablets by Strength (US$), April'2022
  • Figure 4-30: Pramipexole - Recommended Initial & MaintenanceDose Using Immideate Release Tablets (mg/day)
  • Figure 4-31: Pramipexole - Recommended Initial & MaintenanceDose Using Extended Release Tablets (mg/day)
  • Figure 4-32: Ropinirole - Approval Year by Brand Name
  • Figure 4-33: US - Cost of Supply of 100 Ropinirole Oral Tablets by Strength (US$), April'2022
  • Figure 4-34: US - Cost of Supply of 500 Ropinirole Oral Tablets by Strength (US$), April'2022
  • Figure 4-35: US - Cost of Supply of 30 Ropinirole Oral Extended Release Tablets by Strength (US$), April'2022
  • Figure 4-36: US - Cost of Supply of 90 Ropinirole Oral Extended Release Tablets by Strength (US$), April'2022
  • Figure 4-37: UK - Cost of Supply of 84 Requip Oral Tablets by Strength (GBP/US$), April'2022
  • Figure 4-38: Ropinirole - Weekly Recommende Dose & Maximum Dose of Immediate Release Tablet (mgThree Times a Day)
  • Figure 4-39: Ropinirole - Initial & Maximum Recommended Dose for Extended Release Tablet (mg/day)
  • Figure 4-40: Apomorphine - Approval Year by Brand Name
  • Figure 4-41: US - Kynmobi Patent Approval & Expiration Year
  • Figure 4-42: US - Cost of Supply of 15ml & Price per Unit of Apokyn Subcutaneous Solution (US$), April'2022
  • Figure 4-43: US - Cost of Supply of 30 Transdermal Films & Price per Unit of Kynmobi Transdermal Film (US$), April'2022
  • Figure 4-44: UK - Cost of Supply of 5 Cartridges & Per Unit Price of Dacepton 30mg/3ml (GBP/US$), April'2022
  • Figure 4-45: UK - Cost of Supply of 5 Cartridges & Per Unit Price of Dacepton 100mg/20ml (GBP/US$), April'2022
  • Figure 4-46: UK - Cost of Supply of 5 Prefilled Pens & Per Unit Price of Apo-go 30mg/3ml (GBP/US$), April'2022
  • Figure 4-47: UK - Cost of Supply of 5 Prefilled Pens & Per Unit Price of Apo-go 50mg/10ml (GBP/US$), April'2022
  • Figure 4-48: Apomorphine - Recommended Initial & Maximum Sublingual Dose For Parkinson's Treatment (mg/day)
  • Figure 4-49: Apomorphine - Recommended Initial & Maximum Subcutaneous Dose For Parkinson's Treatment (mg/day)
  • Figure 4-50: Global - Apokyn Quarterely Sales Value (US$ Million), 2021
  • Figure 4-51: Global - Apokyn Quarterely Sales Value (US$ Million), Q2-Q4'2020
  • Figure 4-52: US - Parlodel FDA Approval & 1st Generic Approval Year
  • Figure 4-53: US - Cost of Supply of 30 Capsules & Price per Unit of Parlodel 5mg Capsule (US$), April'2022
  • Figure 4-54: US - Cost of Supply of 100 Capsules & Price per Unit of Parlodel 5mg Capsule (US$), April'2022
  • Figure 4-55: US - Cost of Supply of 30 Tablets & Price per Unit of Parlodel 2.5mg Tablet (US$), April'2022
  • Figure 4-56: US - Cost of Supply of 100 Tablets & Price per Unit of Parlodel 2.5mg Tablet (US$), April'2022
  • Figure 4-57: US - Cost of Supply of 30 Capsules & Price per Unit of Bromocriptine 5mg Capsule (US$), April'2022
  • Figure 4-58: US - Cost of Supply of 100 Capsules & Price per Unit of Bromocriptine 5mg Capsule (US$), April'2022
  • Figure 4-59: US - Cost of Supply of 30 Tablets & Price per Unit of Bromocriptine 2.5mg Tablet (US$), April'2022
  • Figure 4-60: US - Cost of Supply of 100 Tablets & Price per Unit of Bromocriptine 2.5mg Tablet (US$), April'2022
  • Figure 4-61: Bromocriptine - Recommended Initial & Maximum Dose For Parkinson's Treatment (mg/day)
  • Figure 5-1: Selegiline - Approval Year by Brand Name
  • Figure 5-2: US - Cost of Supply of 60 Tablets & Price per Unit of Zelapar Disintegrating Tablet (US$), April'2022
  • Figure 5-3: US - Cost of Supply of 60 Capsules & Price per Unit of Eldepryl 5mg Capsule (US$), April'2022
  • Figure 5-4: UK - Cost of Supply of 60 Capsules & Price per Unit of Eldepryl 5mg Capsule (GBP/US$), April'2022
  • Figure 5-5: US - Cost of Supply of Selegiline 5mg Capsules by Packaging (US$), April'2022
  • Figure 5-6: US - Cost of Supply of 60 Tablets & Price per Unit of Selegiline Oral Tablet (US$), April'2022
  • Figure 5-7: US - Cost of Supply of 500 Tablets & Price per Unit of Selegiline Oral Tablet (US$), April'2022
  • Figure 5-8: Selegiline - Recommended Initial & Maximum Dose with Disintegrating Tablet (mg/day)
  • Figure 5-9: Selegiline - Maximum Recommended Dose by Product Type (mg/day)
  • Figure 5-10: Xadago - Approval Year by Region
  • Figure 5-11: US - Xadago Patent Approval & Expiration Year
  • Figure 5-12: US - Cost of Supply of 30 Tablets & Price per Unit of Xadago Oral Tablet (US$), April'2022
  • Figure 5-13: UK - Cost of Supply of 30 Tablets & Price per Unit of Xadago Oral Tablet (GBP/US$), April'2022
  • Figure 5-14: Xadago - Recommended Initial & Incrimented Dose For Parkinson's Treatment (mg/day)
  • Figure 5-15: Global - Xadago Quarterely Sales Value (US$ Million), Q1-Q3'2021
  • Figure 5-16: Global - Xadago Quarterely Sales Value (US$ Million), Q2-Q4'2020
  • Figure 5-17: Azilect - Approval Year by Region
  • Figure 5-18: US - Azilect FDA Approval & 1st Generic Approval Year
  • Figure 5-19: US - Azilect FDA Approval & Patent Expiration Year
  • Figure 5-20: US - Cost of Supply of 30 Tablets & Price per Unit of Azilect Oral Tablet (US$), April'2022
  • Figure 5-21: US - Cost of Supply of 30 Tablets & Price per Unit of Rasagiline 0.5mg Oral Tablet (US$), April'2022
  • Figure 5-22: US - Cost of Supply of 30 Tablets & Price per Unit of Rasagiline 1mg Oral Tablet (US$), April'2022
  • Figure 5-23: UK - Cost of Supply of 28 Tablets & Price per Unit of Rasagiline Oral Tablet (GBP/US$), April'2022
  • Figure 5-24: UK - Cost of Supply of 28 Tablets & Price per Unit of Azilect Oral Tablet (GBP/US$), April'2022
  • Figure 5-25: Recommeded Dose for Monotherapy & Adjuvant Therapy in Concomitant Levodopa/ NonLevodopa Patients (mg/day)
  • Figure 6-1: Comtan - Approval Year by Region
  • Figure 6-2: US - Comtan FDA Approval & 1st Generic Approval Year
  • Figure 6-3: US - Cost of Supply of 100 Tablets & Price per Unit of Comtan Oral Tablet (US$), April'2022
  • Figure 6-4: US - Cost of Supply of 30 Tablets & Price per Unit of Entacapone Oral Tablet (US$), April'2022
  • Figure 6-5: US - Cost of Supply of 50 Tablets & Price per Unit of Entacapone Oral Tablet (US$), April'2022
  • Figure 6-6: US - Cost of Supply of 100 Tablets & Price per Unit of Entacapone Oral Tablet (US$), April'2022
  • Figure 6-7: UK - Cost of Supply of 30 Tablets & Price per Unit of Comtess Oral Tablet (GBP/US$), April'2022
  • Figure 6-8: UK - Cost of Supply of 100 Tablets & Price per Unit of Comtess Oral Tablet (GBP/US$), April'2022
  • Figure 6-9: Entacapone - Recommended Initial & Maximum Dose (mg/day)
  • Figure 6-10: Tasmar - Approval Year by Region
  • Figure 6-11: US - Tasmar FDA Approval & 1st Generic Approval Year
  • Figure 6-12: US - Cost of Supply of 90 Tablets & Price per Unit of Tasmar Oral Tablet (US$), April'2022
  • Figure 6-13: US - Cost of Supply of 90 Tablets & Price per Unit of Tolacapone Oral Tablet (US$), April'2022
  • Figure 6-14: UK - Cost of Supply of 100 Tablets & Price per Unit of Tesmar Oral Tablet (GBP/US$), April'2022
  • Figure 6-15: Tolcapone - Recommended Initial & Maximum Dose (mg/day)
  • Figure 6-16: Stalevo - Approval Year by Region
  • Figure 6-17: US - Stalevo FDA Approval & 1st Generic Approval Year
  • Figure 6-18: US - Cost of Supply of 100 Tablets & Price per Unit of Stalevo Oral Tablet (US$), April'2022
  • Figure 6-19: US - Cost of Supply of 100 Tablets & Price per Unit of Carbidopa/Entacapone/Levodopa of 50mg, 75mg, 100mg, & 150mg Oral Tablet (US$), April'2022
  • Figure 6-20: US - Cost of Supply of 100 Tablets & Price per Unit of Carbidopa/Entacapone/Levodopa of 125mg Oral Tablet (US$), April'2022
  • Figure 6-21: US - Cost of Supply of 100 Tablets & Price per Unit of Carbidopa/Entacapone/Levodopa of 200mg Oral Tablet (US$), April'2022
  • Figure 6-22: UK - Cost of Supply of 100, 30 Tablets & Per Unit Price of Stalevo Oral Tablet (GBP/US$), April'2022
  • Figure 6-23: Stalevo - Recommended Maximum Tablets for Parkinson's Treatment by Strength
  • Figure 6-24: Stalevo - Approval Year by Region
  • Figure 6-25: US - Osmolex Patent Approval & Expiration Year
  • Figure 6-26: US - Cost of Supply of 30 Capsules & Price per Unit of Ongentys Oral Capsule (US$), April'2022
  • Figure 6-27: UK - Cost of Supply of 30 Capsules & Per Unit Price of Ongentys Oral Capsule (GBP/US$), April'2022
  • Figure 6-28: Ongentys - Recommended Initial & Dose Reduction for Parkinson's Treatment by Strength (mg/day)
  • Figure 7-1: US - Tasmar FDA Approval & 1st Generic Approval Year
  • Figure 7-2: US - Cost of Supply of 100ml & Per Unit Price of Cogentin 1mg/ml Injectable Solution (US$), April'2022
  • Figure 7-3: US - Cost of Supply of 100ml & Per Unit Price of Benztropine 1mg/ml Injectable Solution (US$), April'2022
  • Figure 7-4: US - Cost of Supply of 100 & 1000 Oral Benztropine 0.5mg Tablets (US$), April'2022
  • Figure 7-5: US - Cost of Supply of 100, 180, 540 & 1000 Oral Benztropine 1mg Tablets (US$), April'2022
  • Figure 7-6: US - Cost of Supply of 100, 180, 540 & 1000 Oral Benztropine 2mg Tablets (US$), April'2022
  • Figure 7-7: Benztropine - Recommended Initial Dose & Maximum Dose (mg/day)
  • Figure 7-8: Amantadine - FDA Approval Year by Brand Name
  • Figure 7-9: US - Osmolex Patent Approval & Expiration Year
  • Figure 7-10: US - Osmolex Patent Approval & Expiration Year
  • Figure 7-11: US - Cost of Supply of 60 Capsules & Per Unit Price of Gocovri Extended Release Capsule (US$), April'2022
  • Figure 7-12: US - Cost of Supply of 60 Tablets & Per Unit Price of Osmolex 129 mg-193 mg Extended Release Tablet (US$), April'2022
  • Figure 7-13: US - Cost of Supply of 30 Tablets & Per Unit Price of Osmolex 129 mg Extended Release Tablet (US$), April'2022
  • Figure 7-14: US - Cost of Supply of 30 Tablets & Per Unit Price of Osmolex 193 mg Extended Release Tablet (US$), April'2022
  • Figure 7-15: US - Cost of Supply of 90 Tablets & Per Unit Price of Osmolex 129 mg &193 mg Extended Release Tablet (US$), April'2022
  • Figure 7-16: US - Cost of Supply of 100 Tablets & Per Unit Price of Amantidine Oral Tablets (US$), April'2022
  • Figure 7-17: US - Cost of Supply of 500 Tablets & Per Unit Price of Amantidine Oral Tablets (US$), April'2022
  • Figure 7-18: US - Cost of Supply of 473ml & Per Unit Price of Amantidine Oral Syrup (US$), April'2022
  • Figure 7-19: US - Cost of Supply of 1000ml & Per Unit Price of Amantidine Oral Syrup (US$), April'2022
  • Figure 7-20: US - Cost of Supply of 30, 50, 100 & 1000 Amantidine Oral Capsules (US$), April'2022
  • Figure 7-21: Amantidine - Recommended Initial & Maximum Dose for Extended Release Capsules (mg/day)
  • Figure 7-22: Amantidine - Recommended Initial & Maximum Dose for Extended Release Capsules (mg/day)
  • Figure 7-23: Amantidine - Recommended Initial & Maximum Dose for Immediate Release Formulations (mg/day)
  • Figure 7-24: Global - Gocovri Annual Sales Value (US$ Million), 2020 & 2021
  • Figure 7-25: Global - Gocovri Quarterely Sales Value (US$ Million), 2021
  • Figure 7-26: Global - Gocovri Quarterely Sales Value (US$ Million), 2020
  • Figure 7-27: US - Nourianz Patent Approval & Expiration Year
  • Figure 7-28: US - Cost of Supply of 90 Tablets & Per Unit Price of Nourianz Oral Tablets (US$), April'2022
  • Figure 7-29: Nourianz - Recommended Initial & Maintenance Dose (mg/Day),
  • Figure 7-30: Nourianz - Maximum Daily, Monthly & Annual Treatment Cost (US$), April'2022
  • Figure 7-31: Exelon - Approval Year by Region
  • Figure 7-32: US - Exelon FDA Approval & 1st Generic Approval Year
  • Figure 7-33: US - Cost of Supply of 30 Films & Per Unit Price of Exelon Transdermal Films (US$), April'2022
  • Figure 7-34: US - Cost of Supply of 30 Films & Per Unit Price of Rivastigmine 4.6mg/24hr Transdermal Films (US$), April'2022
  • Figure 7-35: US - Cost of Supply of 30 Films & Per Unit Price of Rivastigmine 9.6mg/24hr Transdermal Films (US$), April'2022
  • Figure 7-36: US - Cost of Supply of 30 Films & Per Unit Price of Rivastigmine 13.3mg/24hr Transdermal Films (US$), April'2022
  • Figure 7-37: UK - Cost of Supply of 30 Patches & Price per Unit of Exelon Transdermal Patch (GBP/US$), April'2022
  • Figure 7-38: Exelon - Initial & Maintenance Dose for the Treatment of Parkinson's disease (mg/24hr)
  • Figure 7-39: Trihexyphenidyl - Approval Year by Region
  • Figure 7-40: US - Cost of Supply of 473ml & Price per Unit of Trihexyphenidyl 2mg/5ml Elixir (US$), April'2022
  • Figure 7-41: US - Cost of Supply of 480ml & Price per Unit of Trihexyphenidyl 2mg/5ml Elixir (US$), April'2022
  • Figure 7-42: US - Cost of Supply of 100 Tablets & Price per Unit of Trihexyphenidyl 2mg Tablet (US$), April'2022
  • Figure 7-43: US - Cost of Supply of 1000 Tablets & Price per Unit of Trihexyphenidyl 2mg Tablet (US$), April'2022
  • Figure 7-44: US - Cost of Supply of 100 Tablets & Price per Unit of Trihexyphenidyl 2mg Tablet (US$), April'2022
  • Figure 7-45: US - Cost of Supply of 1000 Tablets & Price per Unit of Trihexyphenidyl 5mg Tablet (US$), April'2022
  • Figure 7-46: UK - Cost of Supply of 200ml & Price per Unit of Trihexyphenidyl 5mg/5ml Syrup (GBP/US$), April'2022
  • Figure 7-47: Trihexyphenidyl - Recommended Initial & Maximum Dose For Parkinson's Treatment (mg/day)